Member Info for crumbs

Trial.. we are making modi 1 with ISA's adjuvant now.. no mention of funding in that RNS as C7 pointed out and that was never the case with SCIB1 always was if funds allow there... so to me seems modi 1 is going to now be our first commercially or at least CRUK type non dilutive funded trial... �5mill should cover the smaller cohort revised SCIB1 combo... results in a year of commencing ... �1 mill plus what we have in bank should take us far enough not to need another market raising... all things crossed lol

My thoughts on the CRUK SCIB2 is that money will be spent on the nanovescile delivery... some funds seemingly were already spent there pre SCIB2 trial announcement... it may be we do a tie-up with a 3rd party now for that delivery...

Certainly what may come from moditope patent is not deemed guaranteed enough or coming soon enough to get SCIB1 combo going on time that's true but stll much to come here like I say let us hope that's it for our dilutive raisings....Glad they made this one an OO

Are becoming a potential powerhouse... now I do hope this really is our last dilutive raising and has been a tactical move rather than a forced one... RGs latest retweet points to that is what he wants us to think it is lol... but seeing as this field is fast evolving and we have 2 trials fully funded now with data reads in a year of commencing we have plenty to look forward to just on ImmunoBody alone but so so so much more with moditope and now this new tech and a potential other new platform from PTM... One thing is for sure timelines have dragged but could now speed up and this is still a share to be holding ...as so much potential news still on it's way this year including that commercial news.

Patent next ...and what that may bring

I think we will be getting a proactive broadcast at least

So potential other platform coming too?

Fascinating stuff...

My account for OO now.... not my prefered position but one I had been holding funds back for... new platform defo a sweetener and must say am now getting excitied about our long-time elephant trial actually starting... scancell tech back in trial this year! And in US with the best involved come on team scancell

moditope is going to be given to terminal patients....

I'm not sure he can ever see the bright side lol... over to mr market and mm for a day of fun now but like Boom said not so long ago this sp was 12p anyways ... it's hardly end of world stuff but is the removal of SCIB1 funding that has dragged on too long.. so phew to that!

placebo effect in late-stage melanoma... no, I do not think so

Now a new platform to add to value and open up to potential deal/s... main thing to take from today is yes 12p is low to 17.5p .. grr we holders still get a bite at 12p we retain full IP we gain a new platform and most important of all we get that blooming SCIB1 combo trial going AT LAST! .... over to KF and co in the US now... BTW I have big confidence on the data that will come there and that will add a lot of value to SCIB1/immunoBody... dilution is rubbish and does fit into the AIM pattern we all know and dislike...but size of the eventual prize only grows bigger...in or out is investors choice I reckon we will have a situation like last time here... ii will oversubscribe and pi will not fully take up their OO...

To be fair the sounds about SCIB1 combo always did seem to be towards a possible market raising... not so with moditope though the sounds there seem to be partnership...

Yes and I agree better to be 15p but what I'm saying is as a holder who can buy in OO I will get 12p shares... if on that day sp is 20p who is the winner? if on that day sp is 6p then yeah not me lol... we will see... think we will be hearing from BOD on all this interesting to see who is coming into scancell too... possibly new ii...will calculus be buying more etc...

Expecting some media CH needs to be spinning this new platform to the hilt lol

12p is what I'm getting too as a holder who can take OO shares lets see if sp on day is less or more than 12p before you diss the price

To baffle the market lol...

I agree with that but it is also true SCIB1 at this stage has simply not done enough to get the kind of deal off anyone with the money and expertise to take it forwards to the satisfaction of our BOD at least...of course that the trial is now go is fantastic it is our most valuable product and this trial needs to happen!...so that is exciting and data read out in a year of commencing is great too... as I'm sure we will be in a better position then too... new platform arriving is quite a sweetener too and hope to hear much more about that ... all in all SCIB1 is going into a combo trial in US with the best clinicians and clinics and IP is retained... still feel there will be a modi 1./moditope deal on patent but lets see...over to mr market now...like I say I'm taking my OOs

Fund a trial you mean